Compare · ARAY vs SRTS
ARAY vs SRTS
Side-by-side comparison of Accuray Incorporated (ARAY) and Sensus Healthcare Inc. (SRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARAY and SRTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SRTS is the larger of the two at $38.4M, about 4.6x ARAY ($8.4M).
- ARAY has been more active in the news (11 items in the past 4 weeks vs 5 for SRTS).
- SRTS has more recent analyst coverage (8 ratings vs 4 for ARAY).
- Company
- Accuray Incorporated
- Sensus Healthcare Inc.
- Price
- -
- -
- Market cap
- $8.4M
- $38.4M
- 1M return
- -58.56%
- -
- 1Y return
- -93.00%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- 2016
- News (4w)
- 11
- 5
- Recent ratings
- 4
- 8
Accuray Incorporated
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
Sensus Healthcare Inc.
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Latest ARAY
- Accuray Closes TCW Transaction, Strengthening Balance Sheet to Support Long-Term Value Growth
- Accuray Incorporated filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Accuray Incorporated
- Accuray Announces 1-for-40 Reverse Stock Split
- Accuray Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Accuray Reports Fiscal 2027 First Quarter Financial Results
- Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- VP, Corporate Controller Murphy Michael John converted options into 37,500 shares and covered exercise/tax liability with 12,001 shares, increasing direct ownership by 100% to 50,998 units (SEC Form 4) (for withholding tax)
- CEO La Neve Stephen R. converted options into 312,500 shares and covered exercise/tax liability with 100,001 shares, increasing direct ownership by 1,062% to 232,499 units (SEC Form 4) (tax liability)
- Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Latest SRTS
- SEC Form 10-Q filed by Sensus Healthcare Inc.
- Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
- Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
- Sensus Healthcare to Report Third Quarter 2026 Financial Results and Hold Business Update Conference Call on November 12, 2026
- Director Sachetta Eric bought $225,616 worth of shares (64,841 units at $3.48), increasing direct ownership by 28% to 294,784 units (SEC Form 4)
- Director Sachetta Eric bought $66,682 worth of shares (20,633 units at $3.23), increasing direct ownership by 10% to 229,943 units (SEC Form 4)
- Director Sachetta Eric bought $112,904 worth of shares (34,697 units at $3.25), increasing direct ownership by 20% to 209,310 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Sardano Joseph C bought $60,486 worth of shares (20,000 units at $3.02), increasing direct ownership by 2% to 1,220,293 units (SEC Form 4)
- Director Sachetta Eric bought $97,850 worth of shares (31,000 units at $3.16), increasing direct ownership by 22% to 174,613 units (SEC Form 4)